drugset / Trial / NCT00759083

Bivalirudin PCI Registry in Heparin Induced Thrombocytopenia/Heparin Induced Thrombocytopenia and Thrombosis Syndrome (HIT/HITTS) Patients

NCT00759083

Phase 4 Withdrawn The Medicines Company
NaSingle-groupOpen-labelPrevention

Summary

To monitor the frequency of the development of thrombocytopenia in patients with Heparin Induced Thrombocytopenia/Heparin Induced Thrombocytopenia and Thrombosis Syndrome receiving bivalirudin during Percutaneous Coronary Intervention

Timeline

Start
2008-09
Primary completion
2009-09
Completion
2010-05-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Bivalirudin Peptide 1.75 mg/kg Intravenous